| Catalog_no |
ADMC0751 |
| Product_name |
Afuresertib HCl (GSK-2110183) |
| Category |
抑制剂与激动剂 |
| Size |
10mg/50mg/100mg |
| Price |
1660.00/5000.00/7220.00 |
| Specificity |
Target: PKA . Fields: Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1]
IC50: 0.2 nM (AKT1E17K), 1.3 nM |
| Dilution |
Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1]
IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1] |
| Purification |
>98% |
| Concentration |
靶点：PKA;IC50：Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1]
0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), 4 nM (PKG1β)[1] |
| Storage_stability |
2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
| othername |
Afuresertib，GSK 2110183，GSK2110183 |
| Molecular Weight |
463.78 |
| Notes |
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1]
IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1α), |
| Instructions |
 查看与下载 |
